Could a common Alzheimer's drug sharpen thinking in schizophrenia?
NCT ID NCT04857983
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether adding memantine, a drug used for Alzheimer's, to targeted cognitive training (brain exercises) could improve thinking and daily function in people with schizophrenia or schizoaffective disorder. 62 participants took either memantine or a placebo while completing 30 hours of cognitive training. The goal was to see if memantine enhances the benefits of the training on symptoms, thinking skills, and disability.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
memantine
What this could lead to
If it works, this could point toward a way to improve thinking and daily function in people with schizophrenia.
What could go wrong
This is a small, early-phase study (62 people). The results may not apply to everyone, and memantine may not provide additional benefit over cognitive training alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Teaching Facility (CTF B-403 at UCSD Medical Center)
San Diego, California, 92103, United States